Endokrine Interventionen bei Trägerinnen einer pathogenen Variante in den Genen BRCA1 oder BRCA2

In diesem Artikel stellt die Arbeitsgruppe „Hormone“ des „Deutschen Konsortiums für Familiären Brust- und Eierstockkrebs“ relevante Fragestellungen, Statements und Empfehlungen zu oraler Kontrazeption, ovarieller Stimulation im Rahmen einer Kinderwunschbehandlung, Hormonsubstitution nach risikoreduzierender Salpingoophorektomie (RRSO) und Behandlung von Symptomen in der Peri- und Postmenopause vor.

Schlüsselwörter

BRCA - orale Kontrazeption - Hormone - Mammakarzinom - Ovarialkarzinom

• Literatur

• 1 Ortmann O, Schüler-Toprak S, Kast K. The risk of endocrine interventions in carriers of a genetic predisposition for breast and gynecologic cancers: recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer. J Cancer Res Clin Oncol 2024; 150: 417
• 2 AWMF. S3-Guideline Diagnosis, Treatment and Follow-up of malignant Ovarian Tumors: AWMF-Registrynumber: 032–035OL; Version 6.0. 2024 Accessed March 16, 2025 at: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Ovarialkarzinom/Version_6/LL_Ovarialkarzinom_Langversion_6.0.pdf
• 3 Beral V, Doll R, Hermon C. et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371: 303-314
• 4 Soini T, Hurskainen R, Grénman S. et al. Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube. Acta Oncol 2016; 55: 1281-1284
• 5 van den Brandt PA, Goldbohm RA. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-1727
• 6 Cibula D, Gompel A, Mueck AO. et al. Hormonal contraception and risk of cancer. Hum Reprod Update 2010; 16: 631-650
• 7 Fitzpatrick D, Pirie K, Reeves G. et al. Combined and progestagen-only hormonal contraceptives and breast cancer risk: A UK nested case-control study and meta-analysis. PLoS Med 2023; 20: e1004188
• 8 Mørch LS, Skovlund CW, Hannaford PC. et al. Contemporary Hormonal Contraception and the Risk of Breast Cancer. N Engl J Med 2017; 377: 2228-2239
• 9 Huber D, Seitz S, Kast K. et al. Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review. Arch Gynecol Obstet 2020; 301: 875-884
• 10 Schrijver LH, Antoniou AC, Olsson H. et al. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. Am J Obstet Gynecol 2021; 225: 51.e1-51.e17
• 11 Phillips K-A, Kotsopoulos J, Domchek SM. et al. Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2. J Clin Oncol 2025; 43: 422-431
• 12 Schrijver LH, Mooij TM, Pijpe A. et al. Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits. J Natl Cancer Inst 2022; 114: 540-552
• 13 Jensen A, Sharif H, Frederiksen K, Kjaer SK. Use of fertility drugs and risk of ovarian cancer: Danish Population Based Cohort Study. BMJ 2009; 338: b249
• 14 Siristatidis C, Sergentanis TN, Kanavidis P. et al. Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer–a systematic review and meta-analysis. Hum Reprod Update 2013; 19: 105-123
• 15 Kessous R, Davidson E, Meirovitz M. et al. The risk of female malignancies after fertility treatments: a cohort study with 25-year follow-up. J Cancer Res Clin Oncol 2016; 142: 287-293
• 16 Sergentanis TN, Diamantaras A-A, Perlepe C. et al. IVF and breast cancer: a systematic review and meta-analysis. Hum Reprod Update 2014; 20: 106-123
• 17 van den Belt-Dusebout AW, Spaan M, Lambalk CB. et al. Ovarian Stimulation for In Vitro Fertilization and Long-term Risk of Breast Cancer. JAMA 2016; 316: 300-312
• 18 Barcroft JF, Galazis N, Jones BP. et al. Fertility treatment and cancers-the eternal conundrum: a systematic review and meta-analysis. Hum Reprod 2021; 36: 1093-1107
• 19 Huber D, Seitz S, Kast K. et al. Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and breast cancer: a systematic review. Arch Gynecol Obstet 2020; 302: 715-720
• 20 Perri T, Lifshitz D, Sadetzki S. et al. Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers. Fertil Steril 2015; 103: 1305-1312
• 21 Gronwald J, Glass K, Rosen B. et al. Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Fertil Steril 2016; 105: 781-785
• 22 Kotsopoulos J, Librach CL, Lubinski J. et al. Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study. Cancer Causes Control 2008; 19: 1111-1119
• 23 Perri T, Naor-Revel S, Eliassi-Revivo P. et al. Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers. Fertil Steril 2021; 116: 538-545
• 24 Liu X, Yue J, Pervaiz R. et al. Association between fertility treatments and breast cancer risk in women with a family history or BRCA mutations: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2022; 13: 986477
• 25 Faubion SS, Kuhle CL, Shuster LT, Rocca WA. Long-term health consequences of premature or early menopause and considerations for management. Climacteric 2015; 18: 483-491
• 26 Georgakis MK, Beskou-Kontou T, Theodoridis I. et al. Surgical menopause in association with cognitive function and risk of dementia: A systematic review and meta-analysis. Psychoneuroendocrinology 2019; 106: 9-19
• 27 Parker WH, Broder MS, Chang E. et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses’ health study. Obstet Gynecol 2009; 113: 1027-1037
• 28 Rocca WA, Grossardt BR, de Andrade M. et al. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 2006; 7: 821-828
• 29 Parker WH, Feskanich D, Broder MS. et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol 2013; 121: 709-716
• 30 Liu J, Jin X, Liu W. et al. The risk of long-term cardiometabolic disease in women with premature or early menopause: A systematic review and meta-analysis. Front Cardiovasc Med 2023; 10: 1131251
• 31 van der Klift M, de Laet CEDH, McCloskey EV. et al. Risk factors for incident vertebral fractures in men and women: the Rotterdam Study. J Bone Miner Res 2004; 19: 1172-1180
• 32 Vega EM, Egea MA, Mautalen CA. Influence of the menopausal age on the severity of osteoporosis in women with vertebral fractures. Maturitas 1994; 19: 117-124
• 33 Vermeulen RFM, van Beurden M, Korse CM. et al. Impact of risk-reducing salpingo-oophorectomy in premenopausal women. Climacteric 2017; 20: 212-221
• 34 Gaba F, Manchanda R. Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers. Best Pract Res Clin Obstet Gynaecol 2020; 65: 46-65
• 35 Challberg J, Ashcroft L, Lalloo F. et al. Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. Br J Cancer 2011; 105: 22-27
• 36 AWMF. S3-Guideline Peri- and Postmenopause – Diagnosis and Interventions: Guideline of the German Society of Gynecology and Obstetrics (S-3 Level, AWMF Registry No. 015–062). 2018 Accessed November 27, 2021 at: https://www.awmf.org/leitlinien/detail/ll/015-062.html
• 37 Huber D, Seitz S, Kast K. et al. Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review. J Cancer Res Clin Oncol 2021; 147: 2035-2045
• 38 Rebbeck TR, Friebel T, Wagner T. et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005; 23: 7804-7810
• 39 Michaelson-Cohen R, Gabizon-Peretz S, Armon S. et al. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy. Eur J Cancer 2021; 148: 95-102
• 40 Dominguez-Valentin M, Sampson JR, Seppälä TT. et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med 2020; 22: 15-25
• 41 Prentice RL, Manson JE, Langer RD. et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009; 170: 12-23
• 42 Manson JE, Chlebowski RT, Stefanick ML. et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013; 310: 1353-1368
• 43 Prentice RL, Aragaki AK, Chlebowski RT. et al. Randomized Trial Evaluation of the Benefits and Risks of Menopausal Hormone Therapy Among Women 50–59 Years of Age. Am J Epidemiol 2021; 190: 365-375
• 44 Chlebowski RT, Anderson GL, Aragaki AK. et al. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA 2020; 324: 369-380
• 45 Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019; 394: 1159-1168
• 46 Anderson GL, Limacher M, Assaf AR. et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-1712
• 47 Cherry N, Gilmour K, Hannaford P. et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 2002; 360: 2001-2008
• 48 Hodis HN, Mack WJ, Lobo RA. et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 135: 939-953
• 49 Viscoli CM, Brass LM, Kernan WN. et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001; 345: 1243-1249
• 50 Beral V, Gaitskell K, Hermon C. et al. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 2015; 385: 1835-1842
• 51 Tempfer CB, Hilal Z, Kern P. et al. Menopausal Hormone Therapy and Risk of Endometrial Cancer: A Systematic Review. Cancers (Basel) 2020; 12: 2195
• 52 Kotsopoulos J, Huzarski T, Gronwald J. et al. Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study. Breast Cancer Res Treat 2016; 155: 365-373
• 53 Kotsopoulos J, Lubinski J, Neuhausen SL. et al. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecol Oncol 2006; 100: 83-88
• 54 Dominick S, Hickey M, Chin J, Su HI. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev 2015; (12) CD007245
• 55 AWMF. S3-Guideline Hormonal Contraception: AWMF-Registrynumber 015/015, Version 1.2. 2020 Accessed May 03, 2025 at: https://register.awmf.org/assets/guidelines/015-015l_S3_Hormonelle_Empfaengnisverhuetung_2020-09.pdf
• 56 AWMF. S3-Guideline Screening, Diagnosis, Treatment and Follow-up of Breast Cancer: AWMF-Registrynumber: 032-045, long version, Version 4.4. 2021 Accessed March 26, 2025 at: https://register.awmf.org/assets/guidelines/032-045OLl_S3_Mammakarzinom_2021-07.pdf
• 57 Kim J, Turan V, Oktay K. Long-Term Safety of Letrozole and Gonadotropin Stimulation for Fertility Preservation in Women With Breast Cancer. J Clin Endocrinol Metab 2016; 101: 1364-1371
• 58 AWMF. S3-Guideline Endometrial Cancer: AWMF-Registrynumber 032/034-OL, long version 2.0. 2022 Accessed May 03, 2025 at: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Endometriumkarzinom/Version_2/LL_Endometriumkarzinom_Langversion_2.0.pdf